Romanian Journal of Military Medicine (Dec 2016)

Ankylosing spondylitis and cardiovascular risk – case report

  • Daniela Anghel,
  • Lucian M. Ciobîcă,
  • Silviu M. Stanciu,
  • Ciprian V. Jurcuț,
  • Gabriel D. Stoicescu,
  • Ioana A. Răduță,
  • Ancuţa Coca

Journal volume & issue
Vol. CXIX, no. 3
pp. 39 – 42

Abstract

Read online

Introduction: Ankylosing spondylitis (AS) is a chronic progressive inflammatory disease of the axial skeleton and peripheral joints associated with HLA B27 antigen and with the predominance of the male gender (with an average between 20 and 30 years old). Case presentation A 48 years old male patient was admitted to our clinic, having a long history regarding this disease since he was 16. This patient has switched 3 therapies with anti TNF alpha agents until now, and we hope to obtain a good response for a long time. During the treatment with Etanercept he presented an acute anterior uveitis which had a good response to therapy. Conclusion: The ankylosing spondylitis management is complicated when we have the possibility to choose only three anti TNF alpha agents. If a patient does not respond to the first or second agent we are constrained to follow the last one. Therefore the principal problem regarding this special case is that the patient is non responder at the last agent. So the question that arises is witch will be the next therapy for this patient?